Also found in: Dictionary, Thesaurus, Wikipedia.


an antilipidemic agent used for treatment of patients with very high serum triglyceride levels (type IV hyperlipoproteinemia) who do not respond to dietary management.


Apo-Gemfibrozil (CA), Dom-Gemfibrozil (CA), Gen-Gemfibrozil (CA), Lopid, Novo-Gemfibrozil (CA), Nu-Gemfibrozil (CA), PMS-Gemfibrozil (CA), Riva-Gemfibrozil (CA)

Pharmacologic class: Fibric acid derivative

Therapeutic class: Antihyperlipidemic

Pregnancy risk category C


Inhibits peripheral lipolysis, resulting in decreased triglyceride levels. Also inhibits synthesis and increases clearance of very-low-density lipoproteins.


Tablets: 600 mg

Indications and dosages

Type IIb hyperlipidemia in patients without coronary artery disease who don't respond to other treatments; adjunctive therapy for types IV and V hyperlipidemia

Adults: 1,200 mg P.O. daily in two divided doses


• Hypersensitivity to drug

• Gallbladder disease

• Severe renal dysfunction

• Hepatic dysfunction


Use cautiously in:

• renal impairment, cholelithiasis, diabetes, hypothyroidism

• pregnant or breastfeeding patients

• children (safety not established).


• Give 30 minutes before a meal.

• Know that before starting drug and throughout therapy, patient should use dietary measures and exercise, as appropriate, to control hyperlipidemia.

Adverse reactions

CNS: fatigue, hypoesthesia, paresthesia, drowsiness, syncope, vertigo, dizziness, headache, seizures

CV: vasculitis

EENT: cataracts, blurred vision, retinal edema, hoarseness

GI: nausea, vomiting, diarrhea, abdominal or epigastric pain, heartburn, flatulence, gallstones, dry mouth

GU: dysuria, erectile dysfunction, decreased male fertility

Hematologic: eosinophilia, anemia, bone marrow hypoplasia, leukopenia, thrombocytopenia

Hepatic: hepatotoxicity

Metabolic: hypoglycemia

Musculoskeletal: joint, back, or muscle pain; myasthenia; myopathy; synovitis; myositis; rhabdomyolysis

Respiratory: cough

Skin: alopecia, rash, urticaria, eczema, pruritus, angioedema

Other: abnormal taste, chills, weight loss, increased risk of bacterial and viral infection, lupuslike syndrome, anaphylaxis


Drug-drug. Chenodiol, ursodiol: decreased gemfibrozil efficacy

Cyclosporine: decreased cyclosporine effects

HMG-CoA reductase inhibitors: increased risk of rhabdomyolysis

Sulfonylureas: increased hypoglycemic effects

Warfarin: increased bleeding risk

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, creatine kinase (CK), glucose, lactate dehydrogenase: increased values

Hematocrit, hemoglobin, potassium, white blood cells: decreased values

Patient monitoring

• Monitor kidney and liver function test results and serum lipid levels.

Watch for signs and symptoms of adverse reactions, especially bleeding tendency and hypersensitivity reaction.

• Monitor periodic blood counts during first year of therapy.

• Check CK level if myopathy occurs.

Patient teaching

• Tell patient to take drug 30 minutes before breakfast and dinner.

Advise patient to immediately report signs or symptoms of anaphylaxis (such as difficulty breathing or rash) or other allergic reactions.

Instruct patient to immediately report unusual bleeding or bruising or muscle pain.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

• Stress importance of diet and exercise in lowering lipid levels.

• Inform patient that he'll undergo regular blood testing during therapy.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.


/gem·fib·ro·zil/ (jem-fib´ro-zil) a hypolipidemic agent used for treatment of patients with very high serum triglyceride levels (type IV hyperlipoproteinemia) who do not respond to dietary management.


(jĕm-fī′brə-zĭl, -fĭb′rə-)
A drug, C15H22O3, used to treat high levels of triglycerides and low levels of HDL.


an antihyperlipidemic agent.
indication It is prescribed for the treatment of hyperlipidemia, specifically high levels of plasma triglycerides.
contraindications Renal or hepatic dysfunction, gallbladder disease, or known hypersensitivity to this drug prohibits its use.
adverse effects Among the adverse effects are abdominal or epigastric pain, urticaria, dizziness, and anemia.


Lopid® Cardiovascular disease A drug that inhibits VLDL synthesis, which ↓ M&M due to CAD, nonfatal MIs and strokes, by ↑ HDL-C and ↓ TGs. See Cholesterol-lowering drugs, Lovastatin, VA-HIT.


A FIBRATE cholesterol-lowering drug. A brand name is Lopid.
References in periodicals archive ?
8%) patients in the gemfibrozil group complained of abdominal distress during the first week of therapy, but they recovered without any intervention.
Gemfibrozil was selected for the study because it is an inexpensive, easy-to-use drug that has been around a long time.
If it is necessary to use both gemfibrozil and a statin--a common scenario--it's important to document the reason.
Who is at risk: Elderly patients, those who took a high dosage of Baycol, and those who also took Baycol and gemfibrozil (Lopid).
He was discharged from the hospital on gemfibrozil, pravastatin, meclizine, and aspirin.
The findings of the Helsinki Heart Study show that men who have a high ratio of low-density lipoprotein (LDP) to high-density lipoprotein (HDP)--low being "bad" cholesterol and high being "good" cholesterol--and high triglyceride levels have a high CHD risk and can benefit substantially from treatment with gemfibrozil.
If as much thinking went into niacin as has gone into gemfibrozil or lovastatin, we'd know how it works and why some types cause liver damage," says Roger Illingworth of the Oregon Health Sciences Center in Portland.
5ml of distilled water, Group B was given pioglitazone 10mg/kg body weight, and Group C was given gemfibrozil 10mg/kg body weight as single morning dose by oral route for a period of 04 weeks in addition to hyperlipidaemic diet.
The use of statins or gemfibrozil reduced the risk of coronary artery disease death, nonfatal MI, revascularization procedures, and stroke to a greater degree in diabetic patients than it did in nondiabetic patients.
If it is necessary to use both gemfibrozil and a statin--a very common scenario--it's important to document the reason for using the combination.
Another cholesterol-lowering drug, gemfibrozil (Lopid), showed a similar difference when measured in the two ways.